Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 1
2006 1
2007 10
2008 8
2009 1
2010 9
2011 14
2012 9
2013 6
2014 2
2015 5
2016 5
2017 5
2018 1
2019 5
2020 3
2021 7
2022 5
2023 3
2024 4
2025 4
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean examorelin (3 results)?
Tesamorelin.
[No authors listed] [No authors listed] 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644039 Free Books & Documents. Review.
Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy. Tesamorelin is given subcutaneously and has major effects on glucose and lipi …
Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodefic …
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, Stanley TL, Hadigan CM, Grinspoon SK, Erlandson KM, Fourman LT. Russo SC, et al. AIDS. 2024 Oct 1;38(12):1758-1764. doi: 10.1097/QAD.0000000000003965. Epub 2024 Jun 20. AIDS. 2024. PMID: 38905488 Free PMC article. Clinical Trial.
OBJECTIVE: Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). ...Tesamorelin was well tolerated with a similar frequency of adverse events, including hyperglycemia, between groups. ...
OBJECTIVE: Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). ...Tesamorel …
Tesamorelin.
Grunfeld C, Dritselis A, Kirkpatrick P. Grunfeld C, et al. Nat Rev Drug Discov. 2011 Feb;10(2):95-6. doi: 10.1038/nrd3362. Nat Rev Drug Discov. 2011. PMID: 21283099
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy....
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by th …
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
Spooner LM, Olin JL. Spooner LM, et al. Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31. Ann Pharmacother. 2012. PMID: 22298602 Review.
All studies relevant to the evaluation of efficacy and safety of tesamorelin in the management of HIV-associated lipodystrophy were included, with a focus on trials completed in humans. ...Limited data support off-label uses of tesamorelin at this time. CONCLUSIONS: …
All studies relevant to the evaluation of efficacy and safety of tesamorelin in the management of HIV-associated lipodystrophy were i …
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
Dhillon S. Dhillon S. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. Drugs. 2011. PMID: 21668043 Review.
Tesamorelin (Egrifta ) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. ...Tesamorelin was generally well tolerated, with treatme …
Tesamorelin (Egrifta ) is a synthetic analogue of human growth hormone-releasing hormone (also known as growth hormone-releasing fact …
Tesamorelin update.
O'Neal R. O'Neal R. BETA. 2010 Summer-Fall;22(4):16-9. BETA. 2010. PMID: 21591600 No abstract available.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA. Rahman OF, et al. J Am Acad Orthop Surg Glob Res Rev. 2026 Jan 2;10(1):e25.00236. doi: 10.5435/JAAOSGlobal-D-25-00236. eCollection 2026 Jan 1. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID: 41490200 Free PMC article. Review.
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF …
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibr …
Tesamorelin, a human growth hormone releasing factor analogue.
Wang Y, Tomlinson B. Wang Y, et al. Expert Opin Investig Drugs. 2009 Mar;18(3):303-10. doi: 10.1517/13543780802707658. Expert Opin Investig Drugs. 2009. PMID: 19243281 Review.
OBJECTIVE: This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potential indications. ...Other potential indications for tesamorelin appear less promising from the current data....
OBJECTIVE: This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potentia …
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Fourman LT, et al. JCI Insight. 2020 Aug 20;5(16):e140134. doi: 10.1172/jci.insight.140134. JCI Insight. 2020. PMID: 32701508 Free PMC article. Clinical Trial.
As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. ...Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. ...
As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. ...Notably, am …
Tesamorelin improves fat quality independent of changes in fat quantity.
Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Lake JE, et al. AIDS. 2021 Jul 15;35(9):1395-1402. doi: 10.1097/QAD.0000000000002897. AIDS. 2021. PMID: 33756511 Free PMC article.
Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, P = 0.29). Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 ( …
Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -9 …
121 results